A cross-sectional study on discordances between Anyplex™ II MTB/MDR and BACTEC MGIT 960 system for assessing susceptibility for Mycobacterium tuberculosis: analysis of clinical specimens from patients with isoniazid-monoresistant, rifampicin-monoresistant, and multidrug-resistant tuberculosis
Kanphai Wongjarit, Pattama Torvorapanit, Suthidee Petsong, Ajcharaporn Sawatpanich, Waritta Sawaengdee, Panadda Dhepakson et al. A cross-sectional study on discordances between Anyplex™ II MTB/MDR and BACTEC MGIT 960 system for assessing susceptibility for Mycobacterium tuberculosis: analysis of clinical specimens from patients with isoniazid-monoresistant, rifampicin-monoresistant, and multidrug-resistant tuberculosis. // Annals of Clinical Microbiology and Antimicrobials. – 2026. – DOI: 10.1186/s12941-026-00864-5. – URL: https://doi.org/10.1186/s12941-026-00864-5
Kanphai Wongjarit, Pattama Torvorapanit, Suthidee Petsong, Ajcharaporn Sawatpanich, Waritta Sawaengdee, Panadda Dhepakson, Suwatchareeporn Rotcheewaphan, & Gompol Suwanpimolkul (2026). A cross-sectional study on discordances between Anyplex™ II MTB/MDR and BACTEC MGIT 960 system for assessing susceptibility for Mycobacterium tuberculosis: analysis of clinical specimens from patients with isoniazid-monoresistant, rifampicin-monoresistant, and multidrug-resistant tuberculosis. Annals of Clinical Microbiology and Antimicrobials. https://doi.org/10.1186/s12941-026-00864-5
Kanphai Wongjarit, et al. “A cross-sectional study on discordances between Anyplex™ II MTB/MDR and BACTEC MGIT 960 system for assessing susceptibility for Mycobacterium tuberculosis: analysis of clinical specimens from patients with isoniazid-monoresistant, rifampicin-monoresistant, and multidrug-resistant tuberculosis.” Annals of Clinical Microbiology and Antimicrobials, 2026. doi:10.1186/s12941-026-00864-5.
@article{Wongjarit2026,
title = {A cross-sectional study on discordances between Anyplex™ II MTB/MDR and BACTEC MGIT 960 system for assessing susceptibility for Mycobacterium tuberculosis: analysis of clinical specimens from patients with isoniazid-monoresistant, rifampicin-monoresistant, and multidrug-resistant tuberculosis},
author = {Wongjarit, Kanphai and Torvorapanit, Pattama and Petsong, Suthidee and Sawatpanich, Ajcharaporn and Sawaengdee, Waritta and Dhepakson, Panadda and Rotcheewaphan, Suwatchareeporn and Suwanpimolkul, Gompol},
journal = {Annals of Clinical Microbiology and Antimicrobials},
year = {2026},
doi = {10.1186/s12941-026-00864-5},
url = {https://doi.org/10.1186/s12941-026-00864-5}
}